title: It's Time to Reassess the High-Density Lipoprotein (HDL) Hypothesis: CSL112, a Novel Promising Reconstituted HDL Formulation.
authors: Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Austria (G.M.).
authors: Gunther
authors: G
authors: Marsche
mesh_terms: D050197:Atherosclerosis / Q000188:drug therapy*; D003324:Coronary Artery Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D008075:Lipoproteins, HDL / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D008297:Male; D016491:Peripheral Vascular Diseases / Q000188:drug therapy*
chemical_list: D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL
keywords: ATP binding cassette transporter A1; Editorials; coronary artery disease; high‐density lipoprotein–raising therapies